"CRISPR Therapy Gains Second FDA Approval for Gene Editing"
TL;DR Summary
The FDA approved Crispr Therapeutics' drug, Casgevy, developed with Vertex Pharmaceuticals, for patients age 12 and older with beta thalassemia, marking the second gene-editing approval for Crispr. The drug was expected to be approved in March but gained early approval, following its approval for sickle cell disease last year. While CRSP stock slipped, VRTX stock rose, with Vertex's stock surging since mid-December. CRSP stock has a strong Relative Strength Rating, and MarketSmith.com shows it sitting on a floor at its 50-day moving average.
Topics:business#beta-thalassemia#crispr#fda-approval#gene-editing#health-and-pharmaceuticals#vertex-pharmaceuticals
- CRSP Stock Dips Despite Snagging A Second Gene-Editing OK; VRTX Stock Continues On Its Warpath Investor's Business Daily
- FDA clears first CRISPR treatment for a second disease, beta thalassemia CNN
- New trial at MUSC could present low-risk treatment option for sickle cell disease Live 5 News WCSC
- CRISPR-based therapy receives expanded approval for beta thalassemia STAT
- Vertex, Crispr Get Second FDA Approval for Gene Therapy Bloomberg
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
78%
375 → 83 words
Want the full story? Read the original article
Read on Investor's Business Daily